Screens people with Stargardt disease for future ACDN-01 eye trials
Checks people with Stargardt disease to see if they may join ACDN-01 trials.
Plain-language title generated from the registry record
Registry title: Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)
Key facts
- Where
- Ann Arbor, Baltimore, Boston, Cincinnati, Dallas, Gainesville, Houston, and San Francisco, United StatesSee the 9 sites
Where in United States
- University of Michigan Kellogg Eye CenterAnn Arbor, United StatesTaking people
- Wilmer Eye Institute at John HopkinsBaltimore, United StatesNo longer taking part
- Boston Children's HospitalBoston, United StatesTaking people
- Massachusetts Eye and EarBoston, United StatesTaking people
- Cincinnati Eye InstituteCincinnati, United StatesTaking people
- Retina Foundation of TexasDallas, United StatesTaking people
- Vitreo Retinal AssociatesGainesville, United StatesTaking people
- Retina Consultants of TexasHouston, United StatesTaking people
- University of San FranciscoSan Francisco, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ascidian Therapeutics, Inc
- Trial code
- NCT06445322
- Record updated
- 9 October 2026
- Original description
This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.Read full original descriptionShow less
Prescreening Study to Identify Potential Participants With ABCA4-related Retinopathy for ACDN-01 Clinical Trials
This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.
Inclusion: Presence of mutations in the ABCA4 gene; ABCA4 retinopathy phenotype (Stargardt disease type 1 or cone-rod dystrophy).
Exclusion: Retinal disease other than ABCA4-related retinopathy; Presence of a medical condition (systemic or ophthalmic), psychiatric condition, including substance abuse disorder, or physical examination or laboratory finding that may in the opinion of the principal investigator and sponsor preclude adherence to the scheduled study visits, safe participation in the study, or affect the results of the study; The presence of pathogenic or likely pathogenic mutations in other genes known to cause cone-rod dystrophy or Stargardt maculopathy.